Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDX3X | O00571 | 3/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9908997 | 0.77 | MAOA (0.40) | DDX3XNOS3NOS1NOS2NOTUM | |
| SCHEMBL22576313 | 0.76 | NOTUM (0.38) | DDX3XNOTUM | |
| SCHEMBL9530296 | 0.76 | — | — | |
| SCHEMBL16674147 | 0.75 | GGPS1 (0.39) | — | |
| SCHEMBL7602050 | 0.75 | CYP19A1 (0.38) | DDX3XNOS3NOS1NOS2PTGS2 | |
| SCHEMBL16264736 | 0.73 | CYP19A1 (0.38) | DDX3XNOS3NOS1NOS2 | |
| SCHEMBL3114912 | 0.73 | CYP19A1 (0.34) | DDX3XNOS3NOS1NOS2NOTUM | |
| SCHEMBL22856966 | 0.72 | CYP19A1 (0.36) | DDX3XNOS3NOS1NOS2 | |
| SCHEMBL20438736 | 0.72 | CYP19A1 (0.36) | DDX3XNOS3NOS1NOS2 | |
| SCHEMBL10447579 | 0.72 | NOTUM (0.54) | DDX3XNOTUMGLAPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11344635-B2 | Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-05-31 | — | — | US | disclosed |
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344635-B2 | Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups | SLC40A1, TAC3, ABCB7 | DDX3X 3630/4885NOS3 722/4885NOS1 2344/4885 |
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | NR1H2, NR1H3, NR1H4 | DDX3X 1935/4885NOS3 1947/4885NOS1 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.